Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats

European Journal of Pharmacology

Volumn 347, Issue 2-3, 1998, Pages 231-236

  Sato, Kazuo ^a,b   Taniuchi, Yuta ^a   Kawasaki, Tomihisa ^a   Hirayama, Fukushi ^a   Koshio, Hiroyuki ^a   Matsumoto, Yuzo ^a  

^a Inst for Drug Discovery Research   (Japan)

^b Tsukuba Medical Center   (Japan)

Author keywords

Arterio venous shunt; Factor Xa inhibitor; Heparin; Thrombin antithrombin III complex; YM 75466

Indexed keywords

[N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID MONOMETHANE SULFATE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ANTITHROMBIN III; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN; MALE; PEPTIDE HYDROLASES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 0032562437     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00101-0     Document Type: Article

References (18)

1. Boneu B., Bes G., Pelzer H., Sie P., Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb. Haemost. 65:1991;28-31.
2. Deguchi K., Noguchi M., Yuwasaki E., Endou T., Deguchi A., Wada H., Murashima S., Nishikawa M., Shirakawa S., Tanaka K., Kusagawa M. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am. J. Hematol. 38:1991;86-89.
3. Dickneite G., Czech J., Keuper H. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Circ. Shock. 42:1994;183-189.
4. Estivals M., Pelzer H., Sie P., Pichon J., Boccalon H., Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br. J. Haematol. 78:1991;421-424.
5. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74:1995;635-639.
6. Kario K., Matsuo T., Kodama K., Matsuo M. Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes. Thromb. Res. 66:1992;509-515.
7. Kario K., Matsuo T., Kobayashi H., Asada R., Matsuo M. 'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler. Thromb. Vasc. Biol. 16:1996;734-741.
8. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb. Haemost. 59:1988;101-106.
9. Pelzer H., Schwarz A., Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb. Haemost. 65:1991;153-159.
10. Peters R.F., Lees C.M., Mitchell K.A., Tweed M.F., Talbot M.D., Wallis R.B. The characterization of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb. Haemost. 65:1991;268-274.
11. Ravanat C., Freund M., Dol F., Cadroy Y., Roussi J., Incardona F., Maffrand J.P., Boneu B., Drouet L., Legrand C., Herbert J.M., Cazenave J.P. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul. Fibrinolysis. 6:1995;446-455.
12. Ravanat C., Freund M., Schuhler S., Grunert P., Meyer L., Cazenave J.P. Species specific immunoassays to measure blood platelet and coagulation activation in the rat. Thromb. Haemost. 76:1996;1090-1095.
13. Rosenberg J.S., Beeler D.L., Rosenberg R.D. Activation of human prothrombin by highly purified human factors V and Xa in presence of human antithrombin. J. Biol. Chem. 250:1975;1607-1617.
14. Sato K., Kawasaki T., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339:1997;141-146.
15. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 123:1998;92-96.
16. Sitko G.R., Ramjit D.R., Stabilito I.I., Lehman D., Lynch J.J., Vlasuk G.P. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation. 85:1992;805-815.
17. Taniuchi, Y., Sakai, Y., Hisamichi, N., Kayama, M., Mano, Y., Sato, K., Hirayama, F., Koshio, H., Matsumoto, Y., Kawasaki, T., 1998. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb. Haemost., in press.
18. Wong P.C., Crain E.J. Jr., Nguan O., Watson C.A., Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb. Res. 83:1996;117-126.